Yaqiong Sun1,2, Jie Wu1, Hui Cai1, Shuyang Wang1, Qiaolan Liu1,3, William J Blot1,4, Xiao Ou Shu1, Qiuyin Cai5. 1. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN, 37232, USA. 2. Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China. 3. West China School of Public Health, Sichuan University, Chengdu, Sichuan, China. 4. International Epidemiology Institute, Rockville, MD, USA. 5. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN, 37232, USA. qiuyin.cai@vanderbilt.edu.
Abstract
PURPOSE: No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA. METHODS: Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer. RESULTS: No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer. CONCLUSION: Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.
PURPOSE: No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA. METHODS: Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer. RESULTS: No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer. CONCLUSION: Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.
Entities:
Keywords:
Autoantibodies; Ezrin; Pancreatic cancer risk; Prospective study
Authors: Lisa B Signorello; Margaret K Hargreaves; Mark D Steinwandel; Wei Zheng; Qiuyin Cai; David G Schlundt; Maciej S Buchowski; Carolyne W Arnold; Joseph K McLaughlin; William J Blot Journal: J Natl Med Assoc Date: 2005-07 Impact factor: 1.798